Career Development Award

职业发展奖

• 批准号: 8447526
• 负责人: ANNETTE FLECKENSTEIN
• 金额: $ 13.22万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2015-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8447526
• 关键词: Acute; Adolescent; Affect; Amphetamines; Animals; Award; Clinical; Cocaine; Cocaine Abuse; Complex; Cytoplasm; Data; Development; Dopamine; Dose; Drug abuse; Drug usage; Event; Funding; Health; Human; Independent Scientist Award; Individual; Injection of therapeutic agent; Investigation; K-Series Research Career Programs; Kinetics; Laboratories; Location; Mediating; Membrane; Methamphetamine; Methylphenidate; Neurons; Pattern; Pharmaceutical Preparations; Pharmacology and Toxicology; Principal Investigator; Process; Property; Public Health; Rattus; Regulation; Reporting; Research; Research Personnel; Residual state; Rodent; Self Administration; Self-Administered; Staging; Subcellular Fractions; Synaptosomes; Technology; Testing; Time; Universities; Utah; Vesicle; clinically relevant; dopamine transporter; insight; methamphetamine abuse; methamphetamine exposure; neurotoxic; neurotoxicity; new technology; novel; professor; programs; psychostimulant; stimulant abuse; vesicular monoamine transporter 2

DESCRIPTION (provided by applicant): This is a Career Development Award proposal for Dr. Annette Fleckenstein. She is a Professor of Pharmacology and Toxicology at the University of Utah. She has been active in drug abuse research for 13 years and has made important contributions to elucidating the effects of psychostimulants on dopamine (DA) transporter (DAT) and vesicular monoamine transporter-2 (\/MAT-2) regulation and function, especially as related to the neurotoxic effects of the amphetamines. The applicant is a current K02 recipient, and this has permitted the applicant to dramatically decrease her institutional responsibilities and devote 75% of her time to research and professional development as described in her application. Renewal of this award is requested so that the applicant can continue directing research which test the hypotheses that: 1) methamphetamine (METH)-induced DAT complex formation is associated with, and may contribute to, the dopaminergic deficits caused by the stimulant; 2) methylphenidate uniquely affects monoaminergic vesicular function and distribution by a mechanism that includes novel shifts in VMAT-2M-mediated DA transport kinetics; and 3) "latter-stage events" related to intracellular DA management are critical for the persistent dopaminergic deficits caused by METH, and that these events are absent in both adolescent rats and those treated with METH during development. Continued support of this K02 award will not only allow the applicant to expand upon these studies, but also develop expertise in technologies new to her laboratory. In particular, funding of the K02 will facilitate the incorporation of self-administration technology into her laboratory that will permit investigation as to whether transporters are altered in that clinically relevant paradigm. Further, renewal of the K02 will allow the applicant to continue and expand interdisciplinary collaborative efforts with researchers both within and outside of the University of Utah as delineated in the proposal.

描述（由申请人提供）：这是一个职业发展奖的建议博士安妮特Fleckenstein。她是犹他州大学的药理学和毒理学教授。她在药物滥用研究领域活跃了13年，并在阐明精神兴奋剂对多巴胺（DA）转运体（DAT）和囊泡单胺转运体-2（MAT-2）调节和功能的影响方面做出了重要贡献，特别是与安非他明的神经毒性作用有关。申请人是目前的K 02接收者，这使得申请人可以大大减少她的机构责任，并将75%的时间用于研究和专业发展，如申请中所述。申请人要求更新该奖项，以便申请人能够继续指导研究，测试以下假设：1）甲基苯丙胺（METH）诱导的DAT复合物形成与兴奋剂引起的多巴胺能缺陷相关，并可能导致多巴胺能缺陷; 2）哌甲酯通过包括VMAT-2 M介导的DA转运动力学的新变化在内的机制独特地影响单胺能囊泡功能和分布;和3）与细胞内DA管理相关的“后期事件”对于由METH引起的持续多巴胺能缺陷是关键的，并且这些事件在青春期大鼠和在发育期间用METH处理的大鼠中均不存在。K 02奖的持续支持不仅使申请人能够扩展这些研究，而且还可以发展其实验室新技术的专业知识。特别是，对K 02的资助将有助于将自我管理技术纳入她的实验室，这将允许调查转运蛋白是否在临床相关范例中发生改变。此外，K 02的更新将允许申请人继续和扩大与犹他州大学内外的研究人员的跨学科合作努力，如提案中所述。